Protocol Design Featured Articles

  1. The Art And Skill Of Caring For Terminally Ill Patients In Clinical Research And Beyond 8/14/2026

    When designing and conducting trials for terminally ill patients, Kamila Novak reminds researchers to act and speak with respect, warmth, and thoughtfulness.

  2. 3 Ways To Solve Data Friction In Modern Clinical Data Management 8/4/2026

    Senior clinical data manager Shasidar Reddy Abbidi shares how to reduce data friction with targeted automation, early standards adoption, and clearer workflows that move data to decisions faster.

  3. The Rare Trials Summit Wants To Produce More Than Conversation 8/3/2026

    The Rare Trials Summit returns to Boston this September with a mission that extends beyond traditional conference presentations. Through interactive workshops and working groups focused on regulatory guidance and pediatric trials, organizers hope to produce practical solutions that help advance rare disease clinical research.

  4. From Signal To Strategy: What Oncology Basket Trials Can Teach Clinical Development Teams 7/29/2026

    AbbVie's Svetlana Kobina discusses how basket trials can help clinical development teams move from early clinical signals to a more disciplined strategy.

  5. To Take On Transverse Myelitis, Researchers Must First Address Heterogeneity And Misguided Outcome Measures 7/29/2026

    UNC researcher Irena Dujmovic Basuroski, MD, Ph.D., discusses why transverse myelitis remains difficult to study, how multicenter collaboration and adaptive trial designs may help, and why better clinical, patient-reported, and biomarker-based measures are essential to advancing treatment.

  6. 4 Hidden Gaps In Clinical Trial Preparation For Small Biotechs 7/28/2026

    Gaps are not always visible at the executive level, but their consequences are very real — affecting timelines, budgets, data quality, and ultimately the likelihood of regulatory success.

  7. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  8. Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy 7/27/2026

    With the help of Beroe Inc.'s Surya Ponnam, discover how per-patient cost (PPC) analytics is evolving into a core capability for balancing cost, quality, speed, and patient outcomes.

  9. Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients 7/24/2026

    CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

  10. Why Protocol Complexity Is Slowing First Patient In — And How Small Sponsors Can Fix Start-Up Inefficiencies 7/23/2026

    Protocol complexity directly affects timelines, costs, and execution quality. Consultant Jessica Cordes explains why this challenge requires sponsors to change their approach to protocol design, feasibility, and start-up.